Literature DB >> 20852878

Current approach to seronegative myasthenia.

Zohar Argov1.   

Abstract

The group of patients with weakness or fatigue who have electrophysiological evidence of neuromuscular transmission defects, but no antibodies against either acetyl choline receptor or muscle specific kinase, need special evaluation and therapeutic consideration. Such seronegative patients may have low affinity antibodies but may also be late onset of a congenital myasthenic syndrome. This review discuss the practical approach toward the condition of seronegative myasthenia.

Entities:  

Mesh:

Year:  2010        PMID: 20852878     DOI: 10.1007/s00415-010-5746-6

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  26 in total

1.  Rapsyn mutations in hereditary myasthenia: distinct early- and late-onset phenotypes.

Authors:  G Burke; J Cossins; S Maxwell; G Owens; A Vincent; S Robb; M Nicolle; D Hilton-Jones; J Newsom-Davis; J Palace; D Beeson
Journal:  Neurology       Date:  2003-09-23       Impact factor: 9.910

2.  Single fibre electromyography in various processes affecting the anterior horn cell.

Authors:  E Stålberg; M S Schwartz; J V Trontelj
Journal:  J Neurol Sci       Date:  1975-04       Impact factor: 3.181

3.  Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis.

Authors:  Y Nemoto; S Kuwabara; S Misawa; N Kawaguchi; T Hattori; M Takamori; A Vincent
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-05       Impact factor: 10.154

4.  Amyotrophic lateral sclerosis. Impairment of neuromuscular transmission.

Authors:  E H Denys; F H Norris
Journal:  Arch Neurol       Date:  1979-04

5.  A common mutation (epsilon1267delG) in congenital myasthenic patients of Gypsy ethnic origin.

Authors:  A Abicht; R Stucka; V Karcagi; A Herczegfalvi; R Horváth; W Mortier; U Schara; V Ramaekers; W Jost; J Brunner; G Janssen; U Seidel; B Schlotter; W Müller-Felber; D Pongratz; R Rüdel; H Lochmüller
Journal:  Neurology       Date:  1999-10-22       Impact factor: 9.910

6.  Seronegative myasthenia gravis: disease severity and prognosis.

Authors:  F Romi; J A Aarli; N E Gilhus
Journal:  Eur J Neurol       Date:  2005-06       Impact factor: 6.089

7.  Synaptic congenital myasthenic syndrome in three patients due to a novel missense mutation (T441A) of the COLQ gene.

Authors:  J S Müller; S Petrova; R Kiefer; R Stucka; C König; S K Baumeister; A Huebner; H Lochmüller; A Abicht
Journal:  Neuropediatrics       Date:  2004-06       Impact factor: 1.947

Review 8.  Seronegative myasthenia gravis.

Authors:  Angela Vincent; John McConville; Maria Elena Farrugia; John Newsom-Davis
Journal:  Semin Neurol       Date:  2004-03       Impact factor: 3.420

9.  Single fiber electromyography in chronic progressive external ophthalmoplegia.

Authors:  D A Krendel; D B Sanders; J M Massey
Journal:  Muscle Nerve       Date:  1987-05       Impact factor: 3.217

10.  Clinical features of the DOK7 neuromuscular junction synaptopathy.

Authors:  Jacqueline Palace; Daniel Lashley; John Newsom-Davis; Judy Cossins; Susan Maxwell; Robin Kennett; Sandeep Jayawant; Yuji Yamanashi; David Beeson
Journal:  Brain       Date:  2007-04-23       Impact factor: 13.501

View more
  4 in total

1.  In response to "current approach to seronegative myasthenia" by Z. Argov.

Authors:  Michal Haran
Journal:  J Neurol       Date:  2010-11-18       Impact factor: 4.849

Review 2.  Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review.

Authors:  Itay Lotan; Mark A Hellmann; Adi Wilf-Yarkoni; Israel Steiner
Journal:  J Neurol       Date:  2020-10-16       Impact factor: 6.682

3.  Dropped head with positive intravenous edrophonium, progressing to myasthenia gravis.

Authors:  Nobuhiro Sawa; Hiroshi Kataoka; Nobuyuki Eura; Satoshi Ueno
Journal:  BMJ Case Rep       Date:  2013-01-31

4.  Tacrolimus as Single-Agent Immunotherapy and Minimal Manifestation Status in Nonthymoma Myasthenia Gravis.

Authors:  Weiwei Duan; Yuyao Peng; Wanlin Jin; Song Ouyang; Huan Yang
Journal:  J Immunol Res       Date:  2021-11-20       Impact factor: 4.818

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.